call on doc glp-1 Micro-dosing vs full-dose GLP-1… which approach is right for you? Not everyone needs the same path. Some bodies respond better to a slower, lower-dose approach focused tolerance and consistency. Others may Starting your first GLP-1 dose?

Ab Woche 12: Die Wirkung stabilisiert sich

(NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management

We evaluated Chattanooga's GLP-1 providers and ranked the top 10 based on patient ratings, verified reviews, provider credentials, pricing transparency, and telehealth availability

CagriSema Clinical Trials Evidence CagriSema's evidence base is unusually strong for a peptide research stack: two large Phase 3 trials with NEJM publications, plus Phase 1b/2 supporting data

Peptides are a toolnot a replacement for lifestyle, and not everyone is a candidate

Lancet (2025)